{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:59:15Z","timestamp":1790135955689,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"crossref","award":["PI19\/01330"],"award-info":[{"award-number":["PI19\/01330"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010556","name":"Conseller\u00eda de Econom\u00eda, Emprego e Industria, Xunta de Galicia","doi-asserted-by":"publisher","award":["IN607B-2022-04"],"award-info":[{"award-number":["IN607B-2022-04"]}],"id":[{"id":"10.13039\/501100010556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012513","name":"CIBERCV","doi-asserted-by":"crossref","award":["CB16\/11\/0026"],"award-info":[{"award-number":["CB16\/11\/0026"]}],"id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012513","name":"CIBERCV","doi-asserted-by":"crossref","award":["CB16\/11\/00420"],"award-info":[{"award-number":["CB16\/11\/00420"]}],"id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Carbohydrate antigen 125 (CA125) is a proteolytic fragment of MUC-16 that is increased in heart failure (HF) and associated with inflammation, fluid overload, and worse adverse events. Our main objective was to study the expression of CA125 on epicardium and its association with inflammation, adipogenesis, and fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Epicardial fat biopsies and blood were obtained from 151 non-selected patients undergoing open heart surgery. Immunohistochemistry, ELISA, or real-time PCR were used for analyzing protein or mRNA expression levels of CA125 and markers of inflammatory cells, fibroblasts, and adipocytes. Epithelial or stromal cells from epicardium were isolated and cultured to identify CA125 and its association with the adipogenesis and fibrosis pathways, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age was 71 (63\u201374) years, 106 patients (70%) were male, and 62 (41%) had an established diagnosis of HF before surgery. The slice of epicardial fat biopsy determined a positive and colorimetric staining on the epithelial layer after incubating with the CA125 M11 antibody, providing the first description of CA125 expression in the human epicardium. Epicardial CA125 showed a strong and positive correlation with markers of inflammation and fibrosis in the epicardial fat tissue while exhibiting a negative correlation with markers of the adipogenesis pathway. This relationship remained significant after adjusting for potential confounders such as a prior HF diagnosis and plasma CA125 levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Epicardial cells express CA125, which is positively associated with inflammatory and fibroblast markers in epicardial adipose tissue. These results suggest that CA125 may be biologically involved in HF progression (transition from adipogenesis to fibrosis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-024-05351-z","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T11:02:56Z","timestamp":1720004576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Carbohydrate antigen 125 on epicardial fat and its association with local inflammation and fibrosis-related markers"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7200-253X","authenticated-orcid":false,"given":"Sonia","family":"Eiras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"de la Espriella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Iglesias-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumeysa","family":"Basdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"N\u00fa\u00f1ez-Caama\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Mart\u00ednez-Cereijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Reija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"S\u00e1nchez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Mi\u00f1ana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"issue":"3","key":"5351_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/carcin\/bgab010","volume":"42","author":"P Giamougiannis","year":"2021","unstructured":"Giamougiannis P, Martin-Hirsch PL, Martin FL. The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia. Carcinogenesis. 2021;42(3):327\u201343.","journal-title":"Carcinogenesis"},{"key":"5351_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev.physiol.70.113006.100659","volume":"70","author":"CL Hattrup","year":"2008","unstructured":"Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70:431\u201357.","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"5351_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jacc.2023.05.016","volume":"82","author":"A Bayes-Genis","year":"2023","unstructured":"Bayes-Genis A, de la Espriella R, N\u00fa\u00f1ez J. CA125 for fluid overload monitoring: a new life for an old tool. J Am Coll Cardiol. 2023;82(2):158\u201360.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"5351_CR4","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/ejhf.2295","volume":"23","author":"J N\u00fa\u00f1ez","year":"2021","unstructured":"N\u00fa\u00f1ez J, de la Espriella R, Mi\u00f1ana G, Santas E, Ll\u00e1cer P, N\u00fa\u00f1ez E, et al. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. Eur J Heart Fail. 2021;23(9):1445\u201357.","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"5351_CR5","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"key":"5351_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.phrs.2017.07.020","volume":"127","author":"AM Smits","year":"2018","unstructured":"Smits AM, Dronkers E, Goumans MJ. The epicardium as a source of multipotent adult cardiac progenitor cells: their origin, role and fate. Pharmacol Res. 2018;127:129\u201340.","journal-title":"Pharmacol Res"},{"issue":"8","key":"5351_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41587-019-0197-9","volume":"37","author":"J Bargehr","year":"2019","unstructured":"Bargehr J, Ong LP, Colzani M, Davaapil H, Hofsteen P, Bhandari S, et al. Epicardial cells derived from human embryonic stem cells augment cardiomyocyte-driven heart regeneration. Nat Biotechnol agosto de. 2019;37(8):895\u2013906.","journal-title":"Nat Biotechnol agosto de"},{"issue":"21","key":"5351_CR8","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jacc.2021.04.003","volume":"77","author":"S Kenchaiah","year":"2021","unstructured":"Kenchaiah S, Ding J, Carr JJ, Allison MA, Budoff MJ, Tracy RP, et al. Pericardial fat and the risk of heart\u00a0failure. J Am Coll Cardiol. 2021;77(21):2638\u201352.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"5351_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","volume":"19","author":"G Iacobellis","year":"2022","unstructured":"Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19(9):593\u2013606.","journal-title":"Nat Rev Cardiol"},{"issue":"15","key":"5351_CR10","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","volume":"137","author":"M Packer","year":"2018","unstructured":"Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614\u201331.","journal-title":"Circulation"},{"issue":"12","key":"5351_CR11","doi-asserted-by":"publisher","first-page":"6502","DOI":"10.3390\/ijms22126502","volume":"22","author":"B Ballester","year":"2021","unstructured":"Ballester B, Milara J, Montero P, Cortijo J. MUC16 is overexpressed in idiopathic pulmonary fibrosis and induces fibrotic responses mediated by transforming growth factor-\u03b21 canonical pathway. Int J Mol Sci. 2021;22(12):6502.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"5351_CR12","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/cells11081264","volume":"11","author":"X Fu","year":"2022","unstructured":"Fu X, Almenglo C, Fernandez \u00c1L, Mart\u00ednez-Cereijo JM, Iglesias-Alvarez D, Duran-Mu\u00f1oz D, et al. The effect of mineralocorticoid receptor 3 antagonists on anti-inflammatory and anti-fatty acid transport profile in patients with heart failure. Cells. 2022;11(8):1264.","journal-title":"Cells"},{"issue":"11","key":"5351_CR13","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1002\/jcp.24619","volume":"229","author":"A Fern\u00e1ndez-Trasancos","year":"2014","unstructured":"Fern\u00e1ndez-Trasancos A, Fandi\u00f1o-Vaquero R, Agra RM, Fern\u00e1ndez AL, Vi\u00f1uela JE, Gonz\u00e1lez-Juanatey JR, et al. Impaired adipogenesis and insulin resistance in epicardial fat-mesenchymal cells from patients with cardiovascular disease. J Cell Physiol. 2014;229(11):1722\u201330.","journal-title":"J Cell Physiol"},{"issue":"5","key":"5351_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jchf.2019.12.005","volume":"8","author":"J N\u00fa\u00f1ez","year":"2020","unstructured":"N\u00fa\u00f1ez J, Bay\u00e9s-Gen\u00eds A, Revuelta-L\u00f3pez E, Ter Maaten JM, Mi\u00f1ana G, Barallat J, et al. Clinical role of CA125 in worsening heart failure. JACC Heart Fail. 2020;8(5):386\u201397.","journal-title":"JACC Heart Fail"},{"issue":"10","key":"5351_CR15","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/ejhf.2664","volume":"24","author":"J N\u00fa\u00f1ez","year":"2022","unstructured":"N\u00fa\u00f1ez J, De La Espriella R, Rossignol P, Voors AA, Mullens W, Metra M, et al. Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology. Eur J Heart Fail. 2022;24(10):1751\u201366.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"5351_CR16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.recesp.2022.08.001","volume":"76","author":"R De La Espriella","year":"2023","unstructured":"De La Espriella R, Cobo M, Santas E, Verbrugge FH, Fudim M, Girerd N, et al. Assessment of filling pressures and fluid overload in heart failure: an updated perspective. Rev Esp Cardiol Engl Ed. 2023;76(1):47\u201357.","journal-title":"Rev Esp Cardiol Engl Ed."},{"key":"5351_CR17","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2023.08","volume":"9","author":"R De La Espriella","year":"2023","unstructured":"De La Espriella R, N\u00fa\u00f1ez-Mar\u00edn G, Codina P, N\u00fa\u00f1ez J, Bay\u00e9s-Gen\u00eds A. Biomarkers to improve decision-making in acute heart failure. Card Fail Rev. 2023;9: e13.","journal-title":"Card Fail Rev"},{"issue":"20","key":"5351_CR18","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","volume":"71","author":"M Packer","year":"2018","unstructured":"Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol. 2018;71(20):2360\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"5351_CR19","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1242\/jcs.00312","volume":"116","author":"C Seelenmeyer","year":"2003","unstructured":"Seelenmeyer C, Wegehingel S, Lechner J, Nickel W. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J Cell Sci. 2003;116(7):1305\u201318.","journal-title":"J Cell Sci"},{"issue":"6","key":"5351_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s001090050232","volume":"76","author":"NL Perillo","year":"1998","unstructured":"Perillo NL, Marcus ME, Baum LG. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med. 1998;76(6):402\u201312.","journal-title":"J Mol Med"},{"issue":"4","key":"5351_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122360","volume":"10","author":"J N\u00fa\u00f1ez","year":"2015","unstructured":"N\u00fa\u00f1ez J, Rabinovich GA, Sandino J, Mainar L, Palau P, Santas E, et al. Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure. PLoS ONE. 2015;10(4): e0122360.","journal-title":"PLoS ONE"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05351-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05351-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05351-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T11:04:24Z","timestamp":1720004664000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05351-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5351"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05351-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complied with the Declaration of Helsinki and was approved by the Galician Clinical Research Ethics Committee (protocol code 2019\/439 and 2023\/240), and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RE reports personal fees from AstraZeneca, Novartis, Boehringer-Ingelheim, and NovoNordisk (outside the submitted work). JN reports personal fees or advisory boards from Alleviant, AstraZeneca, Boehringer Ingelheim, Bayer, Novartis, NovoNordisk, Rovi, and Vifor Pharma (outside the submitted work).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"619"}}